 Home > Medical News >

Medical Research Articles

European Commission approves Astellas XOSPATA ™ for treatment of AML adult patients

 Time of Update: 2020-06-07

method con 6 service menu template sodium test results welding san diego lexapro drug test

yesterday, Invivoscribe, Inc announced that the European Commission (EC) has approved Astellas' Drug (http:// XOSPATA ™ (gilteritinib) as a single therapy for treating adult patients with recurren
NMPA accepts new indications application for the anti-cancer drug Lenvima (Lewema, Lenvatinib, Lenvastini)

 Time of Update: 2020-06-07

raisins weight loss 5 3 exonuclease anti cancer tea chemistry current events iodine

recently, Eisai, a Japanese pharmaceutical company, announced that the company's new application for treatment of differentiated thyroid cancer (DTC) (http:// the anti-cancer drug Lenvima (Levati
GlaxoSmithKline's daily three-in-one inhalation agent ,31 Re-Re-Le is officially launched in China

 Time of Update: 2020-06-07

jersey sheets full anticholinergic toxicity treatment shelf life drug dba full form new world cleaners

GlaxoSmithKline (GSK) recently announced that the daily three-in-one inhalation agent for slow-stop strophic treatment, Trelegy® Ellipta ®, has been officially launched in China. Quanre has previou
Seattle's small molecule tyrosine kinase inhibitor tucatinib key phase 3 trial reaches primary and secondary endpoints

 Time of Update: 2020-06-07

stage 3 cte t2 breast cancer hepatocyte growth factor lab safety activity breast cancer pill

today, Seattle Genetics (http:// announced that its HER-specific oral small molecule tyrosine kinase inhibitor tucatinib, in the treatment of pre-local advanced or metastatic HER2-positive breast
NMPA accepts application sufaninib for new drug from Huang Chinese pharmaceutical company Surufatinib

 Time of Update: 2020-06-07

data translation mercury data science phase locked loops study cancer pancreatic cancer cells

The National medicines (http:// Regulatory Authority (NMPA ) has accepted the application for listing of the new drug (http:// for the treatment of advanced non-pancreatic neuroendocrine tumor
The phase of the phase BIIB0592 trial of the human-derived IgG1 monoclonal antibody reached the main end of the study.

 Time of Update: 2020-06-07

lupus baclofen 5 mg citalopram 40 mg monoclonal antibody nomenclature propylthiouracil 50 mg

today, Biogen company (http:// announced that its humanized IgG1 monoclonal antibody BIIB059, in the treatment of skin lupus (CLE) and systemic lupus (SLE) patients in the stage 2 test (http://
Bayer announces expansion of anticoagulant Xarelto's indications

 Time of Update: 2020-06-07

toradol oral dose 2 5 dimethylfuran 500 mg vitamin national safety month pub 17 2019

Recently, Bayer announced that it will expand the adaptation of the anticoagulant Xarelto (rivaroxaban, Devashaban) for children under the age of 17 diagnosed with venous thrombosis (VTE), including
FDA approves lenVIMA and KEYTRUDA for treatment of patients with advanced endometrial cancer

 Time of Update: 2020-06-07

non 24 drug plus 1 cot 2 dicyclomine weight loss chinese food dundee

today, Atva and Mershadon announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has approved a combination of LENVIMA (Chinese) and KEYTRUDA (Chinese) for the treatment
Weishi's new drug, ® (FYCOMPA®), has been approved by China's State Drug Administration

 Time of Update: 2020-06-07

eddp drug azo drug topiramate drug class drug test preparation clonazepam drug

recently, the State Medicines (http:// Administration of China has approved the use of the Weishi New Drug (http:// The ® (FYCOMPA®) for the use of adults and children 12 years and older with
Aquestive's Liluazole oral membrane agent Exservan received FDA approval a week in advance

 Time of Update: 2020-06-07

fda drug list ros oxidative stress asciminib fda approval approved biosimilars fda new medicines

recently, Aquestive Therapeutics (http:// announced that its development of the Liluzole oral membrane agent Exservan was approved by the U.S FDA (http:// a week ahead of schedule, for the tre
Takeda ALK inhibitor Alunbrig (brigatinib) stage 3 clinical trial shows good long-term efficacy

 Time of Update: 2020-06-07

tyrosine kinase inhibitors model 5 4 manic phase solid phase extraction 6 2 mc

Takeda (http:// announced that its next-generation ALK inhibitor, Alunbrig (brigatinib), had shown good long-term efficacy in the treatment of alK-positive non-small cell lung cancer (NSCLC) pati
FDA grants Baxter's Guibao Orencia breakthrough treatment

 Time of Update: 2020-06-07

2 4 db fda gene therapy protein complex tumor antigens rheumatoid arthritis prevention

today, the U.S FDA (http:// granted its Orencia breakthrough therapy to prevent moderate to severe acute transplantation (GvHD) from non-related donor hema topoietic stem cell transplants, the co
Poxel SA announces positive top-line results for new oral anti-sugar drug imeglimin key phase III TIMES 3 study

 Time of Update: 2020-06-07

what innocence project japan 2020 spectra 1 2 different types sugar analytical development

Recently, Poxel SA Company (http:// announced the positive top-line results of the 36-week open label extension of the new oral sugar-reducing drug imeglimin key PHASE III TIMES 3 study About TI
FDA approves AstraZeneca BTK inhibitor Calquence (acalabrutinib) for treatment of CLL or SLL

 Time of Update: 2020-06-07

small k562 cell line phase 4 clinical trial cell line development cell based meat

today, the u.S FDA (http:// announced approval of AstraZeneca (http:// of the BTK inhibitor Calquence (calabrutinib) as an initial or follow-up therapy for the treatment of chronic lymphatic l
New anti-TB drug with active ingredient Pretomanid gets FDA approval

 Time of Update: 2020-06-07

cystex active ingredient asciminib fda approval rate order differin active ingredient active ingredient plan

recently, it was reported that the new anti-TB new drug (http:// ) funded by BMBF and active ingredient pretomanid was approved by the http:// Administration ( FDA (http:// Pretomanid is par
Skyfall And MorphoSys Announces CD38 Antibody (TJ202/MOR202) licensed by China's State Drug Administration clinical trial

 Time of Update: 2020-06-07

repatha mechanism action vedolizumab mechanism action tenofovir mechanism action rifaximin mechanism action bio company

recently, Tianyuan Biotech (Shanghai) Limited Company (http:// ("Tianyuan Bio") and Germany's MorphoSys Corporation announced that human source monoclonal CD38 antibody (TJ202/MOR202) was approve
Bollinger Ingerham Ethyl Nidanibu softgel (Vegat ®) accepted by China Drug Administration

 Time of Update: 2020-06-07

solid gas phase normal phase hplc double point energy phase transfer catalyst niacin deficiency disease

recently, Bollinger Ingham announced that the China Medicines (http:// Regulatory Authority has formally accepted the application for the registration of the ethyl sulfonate Nidanibu softgel (Veg
I-Mab obtains license for research new drug from China's State Drug Administration

 Time of Update: 2020-06-07

krokodil drug study dentistry viberzi drug tylenol nsaid drug new china sea

recently, I-Mab Biopharma Bio Pharmaceutical (http:// company (http:// and MorphoSys AG, a German biopharmaceutical company, announced that I-Mab had been licensed by the China National Medici
FDA approves REBLOZYL ® for treatment of beta thalassemia

 Time of Update: 2020-06-07

blood cells microscope fda approved probiotics tizanidine drug test hb blood test sunscreen fda approved

today, Celgene and Acceleron Pharma announced that the U.S Food and drug (http:// Regulatory Authority ( FDA (http:// ) has approved THE use of REBLOZY®PT-aamt for the treatment of beta thalasse
FDA supports Horizon's all-humanized monoclonal antibody teprotumumab for treatment of thyroid eye disease

 Time of Update: 2020-06-07

nsaid eye drops www airgas com endometriosis pain treatment 1 2 crown malassezia furfur treatment

, , the FDA 's (http:// announced in that the u.S FDA (http:// the of The of Skin and Eye Drug (http:// advisory (http:// Committee (DODAC) to support the company's all-humanized monoclon

Go to Page

Medical Research Articles

European Commission approves Astellas XOSPATA ™ for treatment of AML adult patients

NMPA accepts new indications application for the anti-cancer drug Lenvima (Lewema, Lenvatinib, Lenvastini)

GlaxoSmithKline's daily three-in-one inhalation agent ,31 Re-Re-Le is officially launched in China

Seattle's small molecule tyrosine kinase inhibitor tucatinib key phase 3 trial reaches primary and secondary endpoints

NMPA accepts application sufaninib for new drug from Huang Chinese pharmaceutical company Surufatinib

The phase of the phase BIIB0592 trial of the human-derived IgG1 monoclonal antibody reached the main end of the study.

Bayer announces expansion of anticoagulant Xarelto's indications

FDA approves lenVIMA and KEYTRUDA for treatment of patients with advanced endometrial cancer

Weishi's new drug, ® (FYCOMPA®), has been approved by China's State Drug Administration

Aquestive's Liluazole oral membrane agent Exservan received FDA approval a week in advance

Takeda ALK inhibitor Alunbrig (brigatinib) stage 3 clinical trial shows good long-term efficacy

FDA grants Baxter's Guibao Orencia breakthrough treatment

Poxel SA announces positive top-line results for new oral anti-sugar drug imeglimin key phase III TIMES 3 study

FDA approves AstraZeneca BTK inhibitor Calquence (acalabrutinib) for treatment of CLL or SLL

New anti-TB drug with active ingredient Pretomanid gets FDA approval

Skyfall And MorphoSys Announces CD38 Antibody (TJ202/MOR202) licensed by China's State Drug Administration clinical trial

Bollinger Ingerham Ethyl Nidanibu softgel (Vegat ®) accepted by China Drug Administration

I-Mab obtains license for research new drug from China's State Drug Administration

FDA approves REBLOZYL ® for treatment of beta thalassemia

FDA supports Horizon's all-humanized monoclonal antibody teprotumumab for treatment of thyroid eye disease